Head & Neck Cancers | Specialty

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer.

Dr. Koyfman on IMRT and SBRT Reirradiation for Head and Neck Cancer

March 16th 2017

Shlomo Koyfman, MD, associate staff, radiation oncology, Cleveland Clinic, discusses intensity-modulated radiation therapy (IMRT) and stereotactic body radiotherapy (SBRT) reirradiation for patients with head and neck cancer.

Dr. Koyfman on Advancements in Technology and Safety of Treatments in Head and Neck Cancer

March 9th 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses advancements in technology and safety of treatments for patients with head and neck cancer.

Dr. Bastholt on Lenvatinib in Thyroid Cancer

March 7th 2017

Lars Bastholt, MD, clinical oncologist, Odense University Hospital, discusses lenvatinib (Lenvima) in patients with thyroid cancer.

Dr. Nikiforov on Reclassifying Subtype of Thyroid Cancer

March 3rd 2017

Yuri E. Nikiforov, MD, PhD, professor of Pathology, vice chair of the Department of Pathology, director, Division of Molecular & Genomic Pathology, University of Pittsburgh, discusses research that demonstrated the need to reclassify a subtype of thyroid cancer as not cancerous.

Expert Discusses Optimizing Adjuvant CRT in Head and Neck Cancer

February 28th 2017

Samuel Swisher-McClure, MD, discusses the results of a recent retrospective, observational cohort study that examined use and survival outcomes of adjuvant chemoradiotherapy in patients with resected locally advanced head and neck cancer.

Researchers Identify Criteria for Refining Adjuvant CRT Use in Head and Neck Cancer

February 27th 2017

The number of positive lymph nodes is an appropriate selection factor in deciding adjuvant chemoradiotherapy use in some patients with locally advanced head and neck cancer.

Specialty Pharmacy: Build, Buy, or Partner

February 22nd 2017

For oncology practices that want to expand specialty pharmacy services on behalf of their patients, should they build, buy, or partner?

Dr. Seiwert on Ongoing Trials in Head and Neck Cancer

February 20th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses ongoing clinical trials in the field of head and neck cancer.

Dr. Vokes on Different Settings in Head and Neck Cancer

February 16th 2017

Everett Vokes, MD, John E. Ultmann professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses different settings of patients with head and neck cancer.

Rozita Yarmand on Tumor Suppressor Gene in Medullary Thyroid Cancer

February 15th 2017

Rozita Yarmand, PhD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders-Research, The University of Texas MD Anderson Cancer Center, discusses how ATF4 targets RET for degradation and is a candidate tumor suppressor gene in medullary thyroid cancer.

Dr. Weiss on Biomarkers in Head and Neck Cancer

February 14th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses biomarkers in head and neck cancer.

Individualized Bioselection Treatment Methods Increase Survival Rates in Laryngeal Cancer

February 13th 2017

Gregory T. Wolf, MD, discusses a novel approach to treating patients with advanced laryngeal cancer.

Jena French on Combinations With Immunotherapy in Thyroid Cancer

February 7th 2017

Jena D. French, PhD, instructor of Medicine, Division of Endocrinology, Metabolism and Diabetes, University of Colorado Denver, discusses combination regimens exploring immunotherapy and lenvatinib as treatment for patients with thyroid cancer.

Dr. Weiss on Next Steps for Immunotherapy in Head and Neck Cancer

February 4th 2017

Jared Weiss, MD, assistant professor, UNC Lineberger Comprehensive Cancer Center, discusses next steps for immunotherapy agents in the treatment of patients with head and neck cancer.

Dr. Schoenfeld on Low-Dose Radiation Plus Immunotherapy in Head and Neck Cancer

February 2nd 2017

Jonathan D. Schoenfeld, MD, MPhil, MPH, director, melanoma radiation oncology, physician, assistant professor of radiation oncology, Harvard Medical School, Dana-Farber Cancer Institute, discusses potential combination regimens of low-dose radiation therapy and immunotherapy to treat patients with head and neck cancer.

Expert Discusses Updated HPV Vaccine Recommendations

January 26th 2017

Lois Ramondetta, MD, discusses the updated recommendations and the importance of advocating for lesser-known HPV-associated cancers.

Dr. Seiwert on Next Steps in Treatment of Patients With Head and Neck Cancer

January 24th 2017

Tanguy I. Seiwert, MD, assistant professor of Medicine, University of Chicago Medicine, discusses the next steps researchers are taking to improve survival outcomes for patients with head and neck cancer.

Dr. Koyfman on the Evolution of Reirradiation Treatment in Head and Neck Cancer

January 19th 2017

Shlomo Koyfman, MD, associate staff, Radiation Oncology, Cleveland Clinic, discusses recent advancements in reirradiation treatment for patients with head and neck cancer.

Dr. Vokes on Recent Progress in the Treatment Landscape of Head and Neck Cancer

January 19th 2017

Everett Vokes, MD, John E. Ultmann Professor of Medicine and Radiation Oncology, physician-in-chief, University of Chicago Medical Center, chair, Department of Medicine, University of Chicago Medicine, discusses recent progress in the treatment landscape of head and neck cancer.

Dr. Dadu on Immunotherapy in Thyroid Cancer

January 14th 2017

Ramona Dadu, MD, assistant professor, Department of Endocrine Neoplasia and Hormonal Disorders, Division of Internal Medicine, The University of Texas MD Anderson Cancer Center, discusses the use of immunotherapy to treat patients with thyroid cancer.